Clinical Outcome after Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Centr...
Clinical Outcome after Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Central Retinal Vein Occlusion
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Purpose: After 48 months, unresolved macular edema secondary to central retinal vein occlusion (CRVO) is present in more than half of the patients treated with ranibizumab/bevacizumab. Switching therapy to aflibercept, a more recent vascular endothelial growth factor-A (VEGF-A) inhibitor, as well as VEGF-B and placental growth factor inhibitor, mig...
Alternative Titles
Full title
Clinical Outcome after Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Central Retinal Vein Occlusion
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1810469120
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1810469120
Other Identifiers
ISSN
0030-3747
E-ISSN
1423-0259
DOI
10.1159/000439223
